Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACHILLES THERAPEUTICS PLC

(ACHL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Certain Options of Achilles Therapeutics plc are subject to a Lock-Up Agreement Ending on 27-SEP-2021.

09/27/2021 EDT

Certain Options of Achilles Therapeutics plc are subject to a Lock-Up Agreement Ending on 27-SEP-2021. These Options will be under lockup for 181 days starting from 30-MAR-2021 to 27-SEP-2021. Details: The directors, executive officers and existing shareholders have entered into lock-up agreements pursuant to which they will not offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any of ordinary shares or ADSs or any securities convertible into or exercisable or exchangeable for ordinary shares or ADSs (including, without limitation, ordinary shares or ADSs or such other securities which may be deemed to be beneficially owned by such directors, executive officers, managers and members in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant) for a period of 180 days after the date of the prospectus without the written consent of J.P. Morgan Securities LLC, BofA Securities, Inc. and Piper Sandler & Co.


© S&P Capital IQ 2021
All news about ACHILLES THERAPEUTICS PLC
01:15pACHILLES THERAPEUTICS : Presents Research Data for Velos Cancer Therapy Manufacturing Proc..
MT
07:44aESGCT 2021 OR54 : Multicentre, prospective research protocol for development of a clonal n..
PU
07:30aACHILLES THERAPEUTICS : Presents Data at the 2021 European Society for Gene and Cell Thera..
AQ
10/12ACHILLES THERAPEUTICS : to join the Northern Alliance Advanced Therapy Treatment Centre co..
AQ
10/12Achilles Therapeutics plc to join the Northern Alliance Advanced Therapy Treatment Cent..
CI
10/01ACHILLES THERAPEUTICS : to Present at Upcoming Scientific Congresses
AQ
09/27Certain Options of Achilles Therapeutics plc are subject to a Lock-Up Agreement Ending ..
CI
09/27Certain Deferred Shares of Achilles Therapeutics plc are subject to a Lock-Up Agreement..
CI
09/27Certain Ordinary Shares of Achilles Therapeutics plc are subject to a Lock-Up Agreement..
CI
09/02ACHILLES THERAPEUTICS : to Present at Upcoming Investor Conferences
AQ
More news
Analyst Recommendations on ACHILLES THERAPEUTICS PLC
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -75,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,89x
Yield 2021 -
Capitalization 297 M 297 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 156
Free-Float 98,1%
Chart ACHILLES THERAPEUTICS PLC
Duration : Period :
Achilles Therapeutics plc Technical Analysis Chart | ACHL | US00449L1026 | MarketScreener
Technical analysis trends ACHILLES THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 7,32 $
Average target price 22,55 $
Spread / Average Target 208%
EPS Revisions
Managers and Directors
Iraj Ali Chief Executive Officer & Director
Robert Coutts Chief Financial Officer
Edwin Moses Chairman
Karl Peggs Chief Medical Officer
Sergio Quezada Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ACHILLES THERAPEUTICS PLC0.00%297
MODERNA, INC.225.04%137 066
LONZA GROUP AG32.03%60 786
IQVIA HOLDINGS INC.42.23%48 830
SEAGEN INC.-0.71%31 638
CELLTRION, INC.-39.42%25 233